Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016

British Journal of Haematology
Vania Tietsche de Moraes HungriaPaula Barreyro

Abstract

Limited data are available regarding contemporary multiple myeloma (MM) treatment practices in Latin America. In this retrospective cohort study, medical records were reviewed for a multinational cohort of 1103 Latin American MM patients (median age, 61 years) diagnosed in 2008-2015 who initiated first-line therapy (LOT1). Of these patients, 33·9% underwent autologous stem cell transplantation (ASCT). During follow-up, 501 (45·4%) and 129 (11·7%) patients initiated second- (LOT2) and third-line therapy (LOT3), respectively. In the LOT1 setting, from 2008 to 2015, there was a decrease in the use of thalidomide-based therapy, from 66·7% to 42·6%, and chemotherapy from, 20·2% to 5·9%, whereas use of bortezomib-based therapy or bortezomib + thalidomide increased from 10·7% to 45·5%. Bortezomib-based therapy and bortezomib + thalidomide were more commonly used in ASCT patients and in private clinics. In non-ASCT and ASCT patients, median progression-free survival (PFS) was 15·0 and 31·1 months following LOT1 and 10·9 and 9·5 months following LOT2, respectively. PFS was generally longer in patients treated with bortezomib-based or thalidomide-based therapy versus chemotherapy. These data shed light on recent trends in the management ...Continue Reading

References

Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboPhilippe Moreau
Sep 27, 2015·Revista brasileira de hematologia e hemoterapia·Carolina MinnicelliTelma Maria Araújo Moura Lemos
Nov 3, 2015·The Lancet Oncology·Kathrin Strasser-WeipplPaul E Goss
Nov 7, 2016·Annals of Hematology·Vania T M HungriaUNKNOWN International Myeloma Working Group Latin America
Feb 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chrissy H Y van Beurden-TanPieter Sonneveld
Apr 30, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Committee
Mar 25, 2018·Cancer Medicine·Maria Paula CuradoDyego L B Souza
Oct 10, 2018·Clinical Lymphoma, Myeloma & Leukemia·Roberto José Pessoa de Magalhães FilhoBrian Durie
Oct 16, 2018·Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi·T H LamR Ching
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

Aug 6, 2019·British Journal of Haematology·Jorge J Castillo
Sep 25, 2020·Hematology, Transfusion and Cell Therapy·Edvan de Queiroz CrusoéLuciana Barreto Herriot
May 29, 2021·Future Oncology·Fernando PetracciMarwan Ghosn
Jun 6, 2021·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Lucas Lacerda de SouzaOslei Paes de Almeida

❮ Previous
Next ❯

Methods Mentioned

BETA
ISS

Clinical Trials Mentioned

NCT02559583

Software Mentioned

CONNECT

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.